Дополнение мексидола к препаратам для профилактики послеоперационного панкреатита на основе современных знаний патогенеза его ранней фазы
С З Каджаева, У. С. Беслекоев, Э. А. Перисаева et al. · Медицинский вестник Башкортостана · 2014
The article presents the results of preventive measures for acute postoperative pancreatitis (APP) in 159 patients using inhibitors of exocrine pancreatic secretion Sandostatin in combination with antioxidant Mexidol and in 173 patients using pancreatic exocrine secretion inhibitor Sandostatin. A significant difference in the incidence of APP, depending on the method of prophylaxis has been shown. Only seven (4.40%) of 159 patients receiving exocrine secretion inhibitor Sandostatin in combination with Mexidol developed APP. Of 173 patients receiving only exocrine secretion inhibitor Sandostatin 19 (10.98%) developed APP. The combined use of Sandostatin with Mexidol yielded a statistically significant improvement in the results of prevention of APP.
Cited by 0 works.